about
New Developments in Chronic Myeloid Leukemia: Implications for TherapyA mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 miceChronic myeloid leukemia: mechanisms of blastic transformationdel(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia.The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinibPrincipal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.Monitoring response and resistance to treatment in chronic myeloid leukemia.Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitorsClonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib TherapyThe impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemiaThe role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseCancer stem cells with genetic instability: the best vehicle with the best engine for cancer.New therapeutic approaches and prognostic factors in chronic myeloid leukemia.Molecular biology of bcr-abl1-positive chronic myeloid leukemia.Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state.Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.Genetic mechanisms of chronic myeloid leukemia blastic transformation.High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature.Blast phase transformation of chronic myelogenous leukemia presenting with central nervous system manifestation.The Role of Aneuploidy in Cancer Evolution.Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawalExpression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells.Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapyExpanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment.Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.Additional cytogenetic aberrations in chronic myeloid leukemia: a single-center experience in the Middle East.Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability
P2860
Q26745669-FCC99BE9-AE43-4C24-88DE-D07444E32804Q28512574-A8C8BF70-84D4-4ADE-AD8E-3D55DE28CEA9Q33968037-99A8BFB4-68FE-4F62-BDCF-E8E2484261FAQ34204486-B5B7C1EB-443D-4A19-A314-483CC29B8E80Q34369606-99CC8105-3A5D-4B21-A442-F4AB5F192C2FQ34443523-9D8C5DF7-7F46-47F8-85C1-953ECFFBF86DQ34761663-92EFFA64-7B11-49C4-8ACB-3400F4BBC3B9Q35595870-E1551B05-55DD-4D3F-98C7-D45A81F656B5Q35667438-00509983-FCF6-4BFE-8FD6-20B55425B404Q36309977-F6E78F14-9260-4352-ABA9-F8D76B90C89EQ36639038-54EB5046-7D79-4747-A311-56AA97FB2AE1Q36788138-F0EA6322-DF37-4A07-A8FF-C85B4D5093A6Q36996117-F43725E2-ABAF-4B50-B042-B42214062313Q37132857-A433180E-8655-4927-B51E-5A651D6AFAA9Q37283128-6F6B8FA3-3D3B-453B-827B-A8A61BF1A191Q37647076-15E7BFC3-EAF1-45C0-93D7-6305A08EF2ACQ37836926-381D8B09-32CF-495A-9D05-D8C64A83C0C6Q37918304-F2B9E19B-252D-43D3-8107-DEAB4FF32BA8Q37983490-80CC78F9-5A59-4DE9-A612-B561F6ECEA5CQ38003163-9AFA58BD-315F-400B-B4BE-73282518A8C6Q38738491-F78DD200-901D-497B-BE0A-FC80D8F86637Q39066291-F66AA228-40C3-4F3B-A5FF-B9957A56A2CDQ39700353-ADF051A8-BB7E-4EAA-9E2D-78B663FBB57EQ40114134-B93E3768-805A-4019-8312-7E65DF4CD263Q40607863-4F6883EE-52D5-4303-8416-CC35D4AAAD63Q41948234-674ABF01-FDA7-4FA9-B3C5-CE121A6F84FAQ41952149-52020822-5CC9-4F41-B0C4-3408C739907EQ42621930-7FB905A4-9C93-4935-8A91-788ECC31C2BAQ43253095-8A21A236-3AC6-4E9D-BD06-451AFA4797ECQ47659016-EFB9C148-2B3C-42E1-A2E5-D9FE364D9FDBQ54950945-307BD9F4-F30A-43A1-95CC-1E029311E3D5Q58023940-0441A28D-97A5-4F12-8391-65894A0FBB4F
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Clonal evolution in chronic myelogenous leukemia.
@ast
Clonal evolution in chronic myelogenous leukemia.
@en
type
label
Clonal evolution in chronic myelogenous leukemia.
@ast
Clonal evolution in chronic myelogenous leukemia.
@en
prefLabel
Clonal evolution in chronic myelogenous leukemia.
@ast
Clonal evolution in chronic myelogenous leukemia.
@en
P1476
Clonal evolution in chronic myelogenous leukemia.
@en
P2093
Michael E O'Dwyer
P304
P356
10.1016/J.HOC.2004.03.012
P577
2004-06-01T00:00:00Z